A number of other brokerages also recently issued reports on AKBA. Zacks Investment Research upgraded shares of Akebia Therapeutics from a sell rating to a hold rating in a report on Friday, July 12th. JPMorgan Chase & Co. initiated coverage on shares of Akebia Therapeutics in a report on Thursday, May 2nd. They issued an overweight rating and a $12.00 price target for the company. Mizuho set a $16.00 price target on shares of Akebia Therapeutics and gave the company a buy rating in a report on Friday, August 9th. HC Wainwright cut their price target on shares of Akebia Therapeutics from $19.00 to $17.00 and set a buy rating for the company in a report on Tuesday, August 6th. Finally, ValuEngine upgraded shares of Akebia Therapeutics from a sell rating to a hold rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Akebia Therapeutics currently has a consensus rating of Hold and an average price target of $11.88.
AKBA stock opened at $4.30 on Tuesday. Akebia Therapeutics has a one year low of $3.50 and a one year high of $10.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.15 and a current ratio of 1.70. The company has a fifty day moving average of $4.18 and a 200-day moving average of $5.79.
Several institutional investors and hedge funds have recently made changes to their positions in AKBA. Bank of New York Mellon Corp lifted its position in Akebia Therapeutics by 155.1% in the 4th quarter. Bank of New York Mellon Corp now owns 548,595 shares of the biopharmaceutical company’s stock valued at $3,034,000 after acquiring an additional 333,569 shares in the last quarter. Advisor Group Inc. lifted its position in Akebia Therapeutics by 3,206.3% in the 4th quarter. Advisor Group Inc. now owns 9,919 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 9,619 shares in the last quarter. Northern Trust Corp lifted its position in Akebia Therapeutics by 67.9% in the 4th quarter. Northern Trust Corp now owns 1,065,381 shares of the biopharmaceutical company’s stock valued at $5,892,000 after acquiring an additional 430,985 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Akebia Therapeutics by 107.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 942,599 shares of the biopharmaceutical company’s stock valued at $5,212,000 after acquiring an additional 488,972 shares in the last quarter. Finally, Stifel Financial Corp purchased a new stake in Akebia Therapeutics during the 4th quarter valued at $61,000. Institutional investors and hedge funds own 70.64% of the company’s stock.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
Recommended Story: What is a death cross?
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.